Clarity Pharmaceuticals

In a landmark triumph for the radiopharmaceutical industry, the CMS issued its final CY2025 ruling, which will improve patient access to radio-diagnostics, removing financial barriers that tend to restrict access, establish a stable reimbursement stream for clinicians and hospitals administering the products and increase the overall value of the market with a positive impact on future innovation in radiopharmaceuticals.   Clarity’s platform of radio-diagnostic products, including Cu-64 SAR-bisPSMA, Cu-64 SAR-Bombesin and Cu-64 SARTATE in the clinic, as well as other targets in preclinical development, may all benefit from the CMS ruling, bringing Clarity closer to its ultimate goal of improving treatment outcomes for children and adults with cancer.   #cms #biotech #radiodiagnostics

Click below to learn more about the exciting milestones Clarity achieved during and since the September quarter and our plans for future development as we continue to move closer to our ultimate goal of improving treatment outcomes for children and adults with cancer. #biotech #radiopharmaceuticals #TCT

Clarity’s therapeutic product, Cu-67 SAR-bisPSMA, is continuing to generate exciting data in clinical trials and through the U.S. FDA Expanded Access Program (EAP), showcasing its potential as a best-in-class radiopharmaceutical for prostate cancer. Click below to learn more about this next-generation product as it changes the treatment paradigm for patients with prostate cancer in need of better therapies. #PSMA #radiopharmacuticals #biotech

Clarity received positive feedback from the US FDA for a pivotal Phase III trial for 64Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence (BCR). The AMPLIFY trial design is guided by the positive results from the previously completed COBRA and PROPELLER trials and is expected to commence early 2025, recruiting approximately 220 participants.   #radiopharmaceuticals #prostatecancer #PSMA

Clarity has appointed Michelle Parker to the role of Chief Executive Officer (CEO), bringing over 20 years of experience in the industry to the role as the Company is preparing for commercialisation of its best-in-class products and generating strong clinical data to for product approval applications. Dr Colin Biggin will continue his operational focus, leveraging his strong skillset to advance Clarity's supply and manufacturing network in the role of Chief Operating Officer (COO).   #radiopharmaceuticals #CEO #biotech

Clarity’s COBRA trial results were selected for a Top-Rated Oral Presentation at EANM 2024 Congress, one of the most prestigious conferences in nuclear medicine. An abstract on the treatment of metastatic prostate cancer with 67Cu-SAR-bisPSMA was also accepted for presentation. The two abstracts highlight the exciting results of Clarity's SAR-bisPSMA, uniquely positioning this molecule to become best in class for both the treatment and diagnosis of cancer. #nuclearmedicine #prostatecancer #TCT #EANM24 #biotech

Clarity is pleased to release its Annual Report for the financial year ended 30 June 2024. Click below to learn more about the significant milestones we achieved during the financial year as we continue to work towards our ultimate goal of improving treatment outcomes for children and adults with cancer.

Clarity invites analysts and Shareholders to join a webinar presentation on Wednesday 18 September at 10.30am AEST. Executive Chairperson, Dr Alan Taylor, will talk to a number of Clarity’s recent developments, including Board and Executive advancements, as well as exciting new clinical and pre-clinical developments. Register for the webinar: https://lnkd.in/gaYxAWjv Join the conference call: https://lnkd.in/gwNAgMK6 #radiopharmaceuticals #biotech #PSMA #theranostics

Clarity is excited to provide an update on the SECuRE trial. The first multi-dose cohort in the study now advances with no dose limiting toxicities, and efficacy data in the trial continues to be outstanding. Following completion of cohort 4, the trial will advance to the cohort expansion phase.   #PSMA #radiopharmaceuticals #biotech

Clarity is excited to announce Board and senior team changes as the Company progresses through this most exciting period in its history and actively strengthens its pipeline of best-in-class products. #radiopharmaceuticals #biotech #TCT